156 related articles for article (PubMed ID: 12192559)
1. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
[TBL] [Abstract][Full Text] [Related]
2. Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.
Eary JF; Conrad EU; O'Sullivan J; Hawkins DS; Schuetze SM; O'Sullivan F
J Bone Joint Surg Am; 2014 Jan; 96(2):152-8. PubMed ID: 24430415
[TBL] [Abstract][Full Text] [Related]
3. Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.
Rakheja R; Makis W; Tulbah R; Skamene S; Holcroft C; Nahal A; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2013 Jul; 201(1):170-7. PubMed ID: 23789672
[TBL] [Abstract][Full Text] [Related]
4. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis.
Bastiaannet E; Groen H; Jager PL; Cobben DC; van der Graaf WT; Vaalburg W; Hoekstra HJ
Cancer Treat Rev; 2004 Feb; 30(1):83-101. PubMed ID: 14766127
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography (18)F-fluorodeoxyglucose uptake and prognosis in patients with bone and soft tissue sarcoma: A meta-analysis.
Li YJ; Dai YL; Cheng YS; Zhang WB; Tu CQ
Eur J Surg Oncol; 2016 Aug; 42(8):1103-14. PubMed ID: 27189833
[TBL] [Abstract][Full Text] [Related]
6. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Schuetze SM; Rubin BP; Vernon C; Hawkins DS; Bruckner JD; Conrad EU; Eary JF
Cancer; 2005 Jan; 103(2):339-48. PubMed ID: 15578712
[TBL] [Abstract][Full Text] [Related]
7. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.
Skamene SR; Rakheja R; Dahlstrom KR; Roberge D; Nahal A; Charest M; Turcotte R; Hickeson M; Freeman C
J Surg Oncol; 2014 Apr; 109(5):410-4. PubMed ID: 24310279
[TBL] [Abstract][Full Text] [Related]
8. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients.
Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M
AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556
[TBL] [Abstract][Full Text] [Related]
9. Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma.
Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A
Medicine (Baltimore); 2015 Jul; 94(28):e1142. PubMed ID: 26181552
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of (18)F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis.
Kubo T; Furuta T; Johan MP; Ochi M
Eur J Cancer; 2016 May; 58():104-11. PubMed ID: 26990930
[TBL] [Abstract][Full Text] [Related]
11. Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.
Raciborska A; Bilska K; Drabko K; Michalak E; Chaber R; Pogorzała M; Połczyńska K; Sobol G; Wieczorek M; Muszyńska-Rosłan K; Rychlowska-Pruszyńska M; Rodriguez-Galindo C; Dziuk M
Clin Transl Oncol; 2016 Feb; 18(2):189-95. PubMed ID: 26250765
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
[TBL] [Abstract][Full Text] [Related]
13. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
[TBL] [Abstract][Full Text] [Related]
14. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
[TBL] [Abstract][Full Text] [Related]
16. Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer.
Risum S; Loft A; Høgdall C; Berthelsen AK; Høgdall E; Lundvall L; Nedergaard L; Engelholm SA
Acta Oncol; 2011 Apr; 50(3):415-9. PubMed ID: 20698810
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
[TBL] [Abstract][Full Text] [Related]
18. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
[TBL] [Abstract][Full Text] [Related]
20. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]